$7,567.13 speaking Payment -- Teva Pharmaceuticals to Dr. Elizabeth Roberts
Internal Medicine Physician Elizabeth Roberts Earns Over $7,500 for Pharmaceutical Speaking Engagement
This page provides a detailed analysis of a $7,567.13 speaking payment from Teva Pharmaceuticals to Dr. Elizabeth Roberts. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $7,567.13 |
| Payment Type | speaking |
| Payment Nature | Compensation for serving as faculty or as a speaker |
| Pharmaceutical Company | Teva Pharmaceuticals |
| Physician | Dr. Elizabeth Roberts |
| NPI Number | 1987321842 |
| Physician Specialty | Internal Medicine |
| Location | Trenton, NJ |
| Date of Payment | 2024-10-20 |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Teva Pharmaceuticals made a $7.6K speaking payment to Elizabeth Roberts, a Internal Medicine specialist in Trenton, NJ. Elizabeth Roberts received $7,567.13 from Teva Pharmaceuticals for speaking engagements. The payment was for serving as faculty or a speaker, indicating a professional engagement. This payment occurred on October 20, 2024, and was processed in Trenton, NJ.
Patient Guidance: What This Payment Means for You
If you are a patient, this information shows how physicians may receive compensation for sharing their expertise with pharmaceutical companies. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Payments for speaking engagements are common in Internal Medicine, but the amount of $7,567.13 may be higher than average for a single event.
Regulatory Context: Sunshine Act Requirements
This payment falls under the Sunshine Act's reporting requirements, detailing financial relationships between drug manufacturers and healthcare providers.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- physician-compensation
- speaking-fees
- internal-medicine
- teva-pharmaceuticals
- open-payments
Understanding speaking Payments
Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.
Frequently Asked Questions About This Payment
What was this $7.6K payment for?
This was a speaking payment of $7.6K from Teva Pharmaceuticals to Elizabeth Roberts, categorized as "Compensation for serving as faculty or as a speaker". The payment was reported under the Sunshine Act (CMS Open Payments).
Does Elizabeth Roberts accept pharmaceutical money?
Yes, Elizabeth Roberts received this $7.6K payment from Teva Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Elizabeth Roberts's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this speaking payment?
A speaking payment of $7.6K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Internal Medicine?
To compare this payment against Internal Medicine averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Internal Medicine physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Elizabeth Roberts's relationship with Teva Pharmaceuticals?
The payment amount is substantial, suggesting a significant speaking role or multiple engagements. This $7.6K speaking payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Internal Medicine?
The payment type is 'speaking', which is a common way for pharmaceutical companies to engage physicians.
What should patients do after learning about this payment?
If you are a patient, this information shows how physicians may receive compensation for sharing their expertise with pharmaceutical companies.
What else should I know about this speaking payment?
The specific nature of the compensation is 'Compensation for serving as faculty or as a speaker'.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.